English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Claudio De Felice, MD, Endocrine and Metabolism Research Laboratory, National Children’s Medical Research Center, 3-35-31 Taishido, Setagaya-ku, Tokyo 154 (Japan) Dear Sir, Biotinidase (EC 3.5.1.12) is a multiple hydrolase which mainly hydrolyses biotinyl-amido compounds, such as biocytin [1], bio-tinyl-4-aminobenzoate [2] and biotinyl-6aminoquinoline (BAQ) [3]. Although detectable biotinidase activity has been reported in most mammalian tissues and body fluids [4], no enzyme activity in the human urine has been reported to date. Recently, a highly sensitive and specific HPLC-fluorimetric method for a biotinidase assay with BAQ as substrate has been developed by us [5] and subsequently applied to the enzyme determination in the cerebrospi-nal fluid [6]. Using a similar method, biotinidase activity has been detected in the urine of the majority (19/25 = 76%) of patients with renal disease associated with protein-uria, whereas it was non-detectable in 40 healthy, ageand sexmatched Japanese controls [7]. In the present study, the investigation on the biotinidase activity in the urine was extended to healthy non-Japanese individuals. A total of 24 subjects (12 male, 12 female; mean age 25.9 years, range 3.7-44 years) was selected for the present study. The participants were originally from Russia (n = 12), Italy (n = 3), the Czech Republic (n = 3), China (n ≈ 2) the USA (n = 1), South Korea (n = 1), Hungary (n = 1) and Germany (n = 1). At the time of the study, the subjects had been living in Japan, for an average of 15 months (range 1-84 months). The healthy state was ascertained on the basis of a clinical work-up including detailed history, physical examination and standard laboratory tests on blood and urine. The participants were not receiving drugs known to affect the biotin metabolism. Informed consent for the study was obtained. Random, as well as 24-hour urine samples were collected. A 200-μl volume of fresh urine from each sample was filtered (Eki-crodisc 13, pore size 0.2 μm; Gelman Sciences, Japan) and stored at -80°C until the date of the assay. Biotinidase activity using BAQ as enzyme substrate was determined by the HPLCfluorimetric assay, as previously described [5-7]. Enzyme activity was expressed both as pmol·min_1·ml_1 (activity per volume) and pmol·min^·mg-1 of protein (specific activity). Mean intraand in-terassay coefficients of variation were 1.2 and 2.6%, respectively. Urine

Biotinidase Activity in the Urine of Healthy Subjects